X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (151) 151
evolocumab amg 145 (121) 121
humans (108) 108
evolocumab (101) 101
heterozygous familial hypercholesterolemia (97) 97
monoclonal-antibody (89) 89
double-blind (86) 86
hypercholesterolemia (81) 81
statins (80) 80
density-lipoprotein cholesterol (75) 75
subtilisin/kexin type 9 (74) 74
cardiac & cardiovascular systems (65) 65
cholesterol (65) 65
alirocumab (56) 56
placebo-controlled trial (56) 56
pcsk9 (54) 54
low density lipoproteins (53) 53
antibodies, monoclonal - therapeutic use (52) 52
monoclonal antibodies (52) 52
cardiovascular disease (50) 50
pharmacology & pharmacy (50) 50
proprotein convertase 9 - antagonists & inhibitors (49) 49
lipids (47) 47
safety (46) 46
hypercholesterolemia - drug therapy (43) 43
ldl-c (42) 42
anticholesteremic agents - therapeutic use (41) 41
cholesterol, ldl - blood (41) 41
efficacy (40) 40
familial hypercholesterolemia (40) 40
treatment outcome (39) 39
amg 145 (36) 36
coronary-heart-disease (34) 34
lipoproteins (34) 34
pcsk9 inhibition (34) 34
risk factors (34) 34
cardiovascular diseases (33) 33
ldl cholesterol (33) 33
proprotein convertase 9 (32) 32
reducing lipids (32) 32
low density lipoprotein (31) 31
statin therapy (31) 31
cardiology (29) 29
medicine & public health (28) 28
antibodies, monoclonal - adverse effects (27) 27
care and treatment (27) 27
clinical trials (27) 27
statin-intolerant patients (27) 27
male (26) 26
peripheral vascular disease (26) 26
animals (24) 24
atherosclerosis (24) 24
cardiovascular diseases - prevention & control (24) 24
endocrinology & metabolism (24) 24
female (24) 24
proprotein convertase 9 - metabolism (24) 24
proprotein convertase subtilisin/kexin type 9 (24) 24
anticholesteremic agents - adverse effects (23) 23
proprotein convertases - antagonists & inhibitors (23) 23
diabetes (22) 22
pcsk9 inhibitors (22) 22
analysis (21) 21
dyslipidemia (21) 21
middle aged (21) 21
randomized controlled-trial (21) 21
cardiovascular agents (20) 20
low-density lipoprotein cholesterol (20) 20
review (20) 20
hypercholesterolemia - blood (19) 19
ldl-cholesterol (19) 19
low-density-lipoprotein (19) 19
proprotein convertase subtilisin (19) 19
biomarkers - blood (18) 18
cardiovascular (18) 18
high cardiovascular risk (18) 18
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (18) 18
patients (18) 18
randomized-trial (18) 18
autosomal-dominant hypercholesterolemia (17) 17
hyperlipidemia (17) 17
medical research (17) 17
subtilisin (17) 17
abridged index medicus (16) 16
cardiovascular risk (16) 16
dyslipidemias - drug therapy (16) 16
kexin (16) 16
medicine, general & internal (16) 16
risk (16) 16
diabetes mellitus (15) 15
ezetimibe (15) 15
hypolipidemic agents - therapeutic use (15) 15
medicine, research & experimental (15) 15
mutation (15) 15
proprotein convertase 9 - immunology (15) 15
serine-protease (15) 15
antibodies (14) 14
antibodies, monoclonal - pharmacology (14) 14
anticholesteremic agents - pharmacology (14) 14
cardiovascular-disease (14) 14
clinical trials as topic (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Expert Review of Cardiovascular Therapy, ISSN 1477-9072, 05/2015, Volume 13, Issue 5, pp. 477 - 488
Evolocumab is a fully human monoclonal IgG2 antibody that inhibits proprotein convertase subtilisin/kexin type 9, a protein that targets LDL receptors for... 
cardiovascular disease | PCSK9 | LDL cholesterol | hypercholesterolemia | evolocumab
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 16, pp. 1500 - 1509
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 07/2015, Volume 163, Issue 1, pp. 40 - 51
Journal Article
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
Journal Article
Circulation Journal, ISSN 1346-9843, 04/2019, Volume 83, Issue 5, pp. 971 - 977
Background: Treatment with evolocumab reduces mean low-density lipoprotein cholesterol (LDL-C) up to 75% and cardiovascular events by 16% in the first year and... 
CARDIAC & CARDIOVASCULAR SYSTEMS | PCSK9 inhibitor | EFFICACY | SAFETY | Evolocumab | Japan | Low-density lipoprotein cholesterol | AMG 145
Journal Article